BACKGROUND: Colorectal cancer (CRC) rates in low-resource countries, which typically lack CRC screening programs, are rising. This study determined whether a risk model for patients with rectal bleeding could identify patients with curable CRC. METHODS: This prospective, cross-sectional study evaluated a model constructed from data from 1 hospital and validated at 2 other hospitals. The primary endpoint was the ability of the model to predict CRC, as diagnosed by colonoscopy, from clinical characteristics. The secondary endpoint was to determine the percentage of patients who had CRC. RESULTS: Consecutive patients who were 45 years old or older and had self-reported rectal bleeding for more than 1 week were evaluated. From January 2014 to July 2016, 362 patients answered a questionnaire and underwent colonoscopy. In the validation cohort, 56% of patients with rectal bleeding, weight loss, and changes in bowel habits had CRC, whereas 2% of patients with bleeding alone did. Overall, 18.2% of the patients had CRC, and 8.6% had adenomas. The proportion of CRC patients with potentially curable stage II or III disease was 74%, whereas the historical rate was 36%. The combination of rectal bleeding with both symptoms significantly predicted CRC in the validation set (odds ratio, 12.8; 95% confidence interval, 4.6-35.4; P < .001). CONCLUSIONS: In low-resource settings, patients with rectal bleeding, weight loss, and changes in bowel habits should be classified as high risk for CRC. Patients with a high risk score should be prioritized for colonoscopy to increase the number of patients diagnosed with potentially curable CRC. Cancer 2018;124:2766-2773.
BACKGROUND:Colorectal cancer (CRC) rates in low-resource countries, which typically lack CRC screening programs, are rising. This study determined whether a risk model for patients with rectal bleeding could identify patients with curable CRC. METHODS: This prospective, cross-sectional study evaluated a model constructed from data from 1 hospital and validated at 2 other hospitals. The primary endpoint was the ability of the model to predict CRC, as diagnosed by colonoscopy, from clinical characteristics. The secondary endpoint was to determine the percentage of patients who had CRC. RESULTS: Consecutive patients who were 45 years old or older and had self-reported rectal bleeding for more than 1 week were evaluated. From January 2014 to July 2016, 362 patients answered a questionnaire and underwent colonoscopy. In the validation cohort, 56% of patients with rectal bleeding, weight loss, and changes in bowel habits had CRC, whereas 2% of patients with bleeding alone did. Overall, 18.2% of the patients had CRC, and 8.6% had adenomas. The proportion of CRC patients with potentially curable stage II or III disease was 74%, whereas the historical rate was 36%. The combination of rectal bleeding with both symptoms significantly predicted CRC in the validation set (odds ratio, 12.8; 95% confidence interval, 4.6-35.4; P < .001). CONCLUSIONS: In low-resource settings, patients with rectal bleeding, weight loss, and changes in bowel habits should be classified as high risk for CRC. Patients with a high risk score should be prioritized for colonoscopy to increase the number of patients diagnosed with potentially curable CRC. Cancer 2018;124:2766-2773.
Authors: Douglas K Rex; John L Petrini; Todd H Baron; Amitabh Chak; Jonathan Cohen; Stephen E Deal; Brenda Hoffman; Brian C Jacobson; Klaus Mergener; Bret T Petersen; Michael A Safdi; Douglas O Faigel; Irving M Pike Journal: Am J Gastroenterol Date: 2006-04 Impact factor: 10.864
Authors: Nancy N Baxter; Rinku Sutradhar; Shawn S Forbes; Lawrence F Paszat; Refik Saskin; Linda Rabeneck Journal: Gastroenterology Date: 2010-09-18 Impact factor: 22.682
Authors: T Peter Kingham; Olusegun I Alatise; Verna Vanderpuye; Corey Casper; Francis A Abantanga; Thaim B Kamara; Olufunmilayo I Olopade; Muhammad Habeebu; Fatimah B Abdulkareem; Lynette Denny Journal: Lancet Oncol Date: 2013-04 Impact factor: 41.316
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Avinash Sharma; Olusegun I Alatise; Adewale O Adisa; Olukayode A Arowolo; Olalekan Olasehinde; Olusola C Famurewa; Adeleye D Omisore; A O Komolafe; O Olaofe; Aba I Katung; Ayoola D Ibikunle; Ayoola A Egberongbe; Samuel A Olatoke; S O Agodirin; A O Adesiyun; Ademola Adeyeye; K Ibrahim; O A Kolawole; O L Idris; M O Adejumobi; Adebowale I Ajayi; Akinwumi O Olakanmi; Jeremy C Constable; Ken Seier; Mithat Gonen; Murray F Brennan; T Peter Kingham Journal: J Surg Oncol Date: 2019-11-19 Impact factor: 3.454
Authors: Gregory C Knapp; Avinash Sharma; Bolatito Olopade; Olusegun I Alatise; Olalekan Olasehinde; Olujide O Arije; Philip E Castle; T Peter Kingham Journal: World J Surg Date: 2019-11 Impact factor: 3.352
Authors: Anna J Dare; Gregory C Knapp; Anya Romanoff; Olalekan Olasehinde; Olusola C Famurewa; Akinwumi O Komolafe; Samuel Olatoke; Aba Katung; Olusegun I Alatise; T Peter Kingham Journal: Cancer Prev Res (Phila) Date: 2021-09-10
Authors: Gregory C Knapp; Olusegun I Alatise; Olalekan O Olasehinde; Ademola Adeyeye; Omobolaji O Ayandipo; Martin R Weiser; T Peter Kingham Journal: J Glob Oncol Date: 2019-06
Authors: Gregory C Knapp; Olusegun Alatise; Bolatito Olopade; Marguerite Samson; Olalekan Olasehinde; Funmilola Wuraola; Oluwole O Odujoko; Akinwunmi O Komolafe; Olujide O Arije; Philip E Castle; J Joshua Smith; Martin R Weiser; T Peter Kingham Journal: PLoS One Date: 2021-01-12 Impact factor: 3.240